Halozyme (HALO) Q1 FY26 earnings call

Halozyme delivered a strong Q1 FY26, driven by robust growth in ENHANZE royalty revenues and broad-based strength across its portfolio. The company reaffirmed its full-year and 2026-2028 financial guidance, emphasizing durable value creation through existing products and a growing pipeline. Strategic capital allocation includes a new share repurchase program and continued investment in Hypercon and Surf Bio technologies.